A Ciudad

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi The Schizophrenia Outpatient Health Outcomes (SOHO) study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain
    Antonio Ciudad
    Clinical Research, Department of Research and Development, Lilly, S A Avda de la Industria, 30, 28108 Alcobendas, Madrid, Spain
    Eur Psychiatry 23:1-7. 2008
  2. pmc Treatment patterns and health care resource utilization in a 1-year observational cohort study of outpatients with schizophrenia at risk of nonadherence treated with long-acting injectable antipsychotics
    Miguel Bernardo
    Department of Psychiatry, Hospital Clinic, University of Barcelona IDIBAPS CIBERSAM, Barcelona
    Patient Prefer Adherence 5:601-10. 2011
  3. pmc Residual symptoms and functioning in depression, does the type of residual symptom matter? A post-hoc analysis
    Irene Romera
    Department of Clinical Research Lilly, S A Avenida de la Industria 30, 28108, Alcobendas, Spain
    BMC Psychiatry 13:51. 2013
  4. doi Early response and remission as predictors of a good outcome of a major depressive episode at 12-month follow-up: a prospective, longitudinal, observational study
    Antonio Ciudad
    Medical Department, Lilly SA, Alcobendas, Spain
    J Clin Psychiatry 73:185-91. 2012
  5. doi Relapse and therapeutic interventions in a 1-year observational cohort study of nonadherent outpatients with schizophrenia
    Antonio Ciudad
    Department of Clinical Research and Development, Lilly, S A Avenida de la Industria, 30, 28108 Alcobendas, Spain
    Prog Neuropsychopharmacol Biol Psychiatry 36:245-50. 2012
  6. ncbi Safety and effectiveness of olanzapine in monotherapy: a multivariate analysis of a naturalistic study
    Antonio Ciudad
    Lilly Research Laboratories, Avda de la Industria, 30, 28108 Alcobendas, Madrid, Spain
    Prog Neuropsychopharmacol Biol Psychiatry 29:944-51. 2005
  7. ncbi Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial
    Antonio Ciudad
    Clinical Research Unit, Laboratorios Lilly, SA, 28108 Alcobendas, Madrid, Spain
    Prog Neuropsychopharmacol Biol Psychiatry 30:1515-22. 2006
  8. ncbi Remission in schizophrenia: results from a 1-year follow-up observational study
    Antonio Ciudad
    Department of Research and Development, Lilly, S A Avenida de la Industria, 30 E 28108 Alcobendas, Spain
    Schizophr Res 108:214-22. 2009
  9. ncbi Safety and tolerability of olanzapine compared with other antipsychotics in the treatment of elderly patients with schizophrenia: a naturalistic study
    Antonio Ciudad
    Lilly Research Laboratories, 30 Avenida de la Industria, Alcobendas CP28108, Madrid, Spain
    Eur Psychiatry 19:358-65. 2004
  10. ncbi [The European schizophrenia outpatient health outcomes (SOHO) study: baseline findings of the Spanish sample]
    A Ciudad
    Departamento de Investigación Clínica, Eli Lilly and Co, Alcobendas, Madrid
    Actas Esp Psiquiatr 32:227-35. 2004

Collaborators

Detail Information

Publications24

  1. ncbi The Schizophrenia Outpatient Health Outcomes (SOHO) study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain
    Antonio Ciudad
    Clinical Research, Department of Research and Development, Lilly, S A Avda de la Industria, 30, 28108 Alcobendas, Madrid, Spain
    Eur Psychiatry 23:1-7. 2008
    ..This article presents the long-term results in terms of antipsychotic medication maintenance and factors influencing it in a representative sample of patients with schizophrenia recruited in the SOHO study within Spain...
  2. pmc Treatment patterns and health care resource utilization in a 1-year observational cohort study of outpatients with schizophrenia at risk of nonadherence treated with long-acting injectable antipsychotics
    Miguel Bernardo
    Department of Psychiatry, Hospital Clinic, University of Barcelona IDIBAPS CIBERSAM, Barcelona
    Patient Prefer Adherence 5:601-10. 2011
    ....
  3. pmc Residual symptoms and functioning in depression, does the type of residual symptom matter? A post-hoc analysis
    Irene Romera
    Department of Clinical Research Lilly, S A Avenida de la Industria 30, 28108, Alcobendas, Spain
    BMC Psychiatry 13:51. 2013
    ..The degrees to which residual symptoms in major depressive disorder (MDD) adversely affect patient functioning is not known. This post-hoc analysis explored the association between different residual symptoms and patient functioning...
  4. doi Early response and remission as predictors of a good outcome of a major depressive episode at 12-month follow-up: a prospective, longitudinal, observational study
    Antonio Ciudad
    Medical Department, Lilly SA, Alcobendas, Spain
    J Clin Psychiatry 73:185-91. 2012
    ....
  5. doi Relapse and therapeutic interventions in a 1-year observational cohort study of nonadherent outpatients with schizophrenia
    Antonio Ciudad
    Department of Clinical Research and Development, Lilly, S A Avenida de la Industria, 30, 28108 Alcobendas, Spain
    Prog Neuropsychopharmacol Biol Psychiatry 36:245-50. 2012
    ..To evaluate the incidence rate of relapse, the clinical profiles, and the therapeutic interventions employed for patients with schizophrenia deemed as likely nonadherers to oral antipsychotic drugs...
  6. ncbi Safety and effectiveness of olanzapine in monotherapy: a multivariate analysis of a naturalistic study
    Antonio Ciudad
    Lilly Research Laboratories, Avda de la Industria, 30, 28108 Alcobendas, Madrid, Spain
    Prog Neuropsychopharmacol Biol Psychiatry 29:944-51. 2005
    ..This study investigated safety and effectiveness of olanzapine in monotherapy compared with conventional antipsychotics in treatment of acute inpatients with schizophrenia...
  7. ncbi Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial
    Antonio Ciudad
    Clinical Research Unit, Laboratorios Lilly, SA, 28108 Alcobendas, Madrid, Spain
    Prog Neuropsychopharmacol Biol Psychiatry 30:1515-22. 2006
    ..GENERAL PURPOSE: To evaluate the social functioning of schizophrenic outpatients after switching to second-generation antipsychotics...
  8. ncbi Remission in schizophrenia: results from a 1-year follow-up observational study
    Antonio Ciudad
    Department of Research and Development, Lilly, S A Avenida de la Industria, 30 E 28108 Alcobendas, Spain
    Schizophr Res 108:214-22. 2009
    ....
  9. ncbi Safety and tolerability of olanzapine compared with other antipsychotics in the treatment of elderly patients with schizophrenia: a naturalistic study
    Antonio Ciudad
    Lilly Research Laboratories, 30 Avenida de la Industria, Alcobendas CP28108, Madrid, Spain
    Eur Psychiatry 19:358-65. 2004
    ..To evaluate the safety and tolerability of olanzapine in the treatment of elderly patients with schizophrenia...
  10. ncbi [The European schizophrenia outpatient health outcomes (SOHO) study: baseline findings of the Spanish sample]
    A Ciudad
    Departamento de Investigación Clínica, Eli Lilly and Co, Alcobendas, Madrid
    Actas Esp Psiquiatr 32:227-35. 2004
    ..To describe the baseline findings and study population of the Spanish sample of the Schizophrenia Outpatient Health Outcomes (SOHO) Study...
  11. ncbi [Safety and tolerability of olanzapine versus risperidone: a one-year randomized study in outpatients with schizophrenia with prominent negative symptoms]
    A Ciudad
    Departamento de Investigación Clínica, Eli Lilly and Co, Lilly Research Laboratories, Av de la Industria 30, 28108 Alcobendas, Madrid
    Actas Esp Psiquiatr 35:105-14. 2007
    ..To evaluate the safety and tolerability of long-term treatment with olanzapine versus risperidone in schizophrenic outpatients with prominent negative symptoms...
  12. ncbi [Remission and relapse in the outpatient treatment of patients with schizophrenia. Outcomes at 3 years]
    J M Haro
    Fundacion San Juan de Dios, Barcelona, Spain
    Actas Esp Psiquiatr 36:187-96. 2008
    ..Three year data collected in the frame of the SOHO study within Spain were used to evaluate antipsychotic treatment outcomes by analyzing remission and relapse as well as the factors influencing them...
  13. ncbi Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study
    Jose Manuel Montes
    Centro de Salud Mental La Plata La Plata Mental Health Center, University of Alcala de Henares, Travesi a de la Cañada s n Torrejón de Ardoz, 28850, Madrid, Spain
    Prog Neuropsychopharmacol Biol Psychiatry 27:667-74. 2003
    ..This study evaluated the effectiveness, safety, and quality of life (Qol) offered by olanzapine in first-episode schizophrenia...
  14. ncbi Safety, effectiveness, and patterns of use of olanzapine in acute schizophrenia: a multivariate analysis of a large naturalistic study in the hospital setting
    Fernando Cañas
    Psychiatry Unit, Hospital Psiquiatrico de Madrid, Madrid, Spain
    Med Clin (Barc) 124:481-6. 2005
    ..Furthermore, we evaluated patterns of use of olanzapine and their relationship to safety and effectiveness...
  15. ncbi [Economic analyses of olanzapine in the treatment of schizophrenia and bipolar disorder]
    T Dilla
    Departamento de Investigación Clínica, Lilly S A, Madrid
    Actas Esp Psiquiatr 32:269-79. 2004
    ..In the treatment of bipolar disorder, although few studies have estimated the economic impact of olanzapine, it has been observed a reduction of hospitalization costs associated to the treatment with olanzapine...
  16. ncbi Internet in clinical research based on a pilot experience
    Carmen López-Carrero
    Department of Medical Research, Lilly S A, Avda de la Industria 30 28108, Alcobendas, Madrid, Spain
    Contemp Clin Trials 26:234-43. 2005
    ..In short, EDC can dramatically improve the clinical trial process, opening the door to new technologies in the world of clinical research, not only for sponsors, but also for clinicians...
  17. ncbi [Development and validation of the Social Functioning Scale, short version, in schizophrenia for its use in the clinical practice]
    J Alonso
    Health Services Research Unit, Institut Muncipal d Investigació Mèdica, IMIM Hospital del Mar, Barcelona, Spain
    Actas Esp Psiquiatr 36:102-10. 2008
    ..Its length may be difficult to use in clinical practice. The objective of this study was to develop and validate a short version of the SFS...
  18. ncbi Measuring schizophrenia remission in clinical practice
    Jordi Alonso
    Health Services Research Unit, Institut Municipal d Investigacio Medica, Hospital del Mar, Barcelona, Spain
    Can J Psychiatry 53:202-6. 2008
    ..To evaluate reliability and validity of the short forms (SF) assessment of positive (SAPS) and negative (SANS) symptoms scales...
  19. ncbi Symptomatic remission and social/vocational functioning in outpatients with schizophrenia: prevalence and associations in a cross-sectional study
    Luis San
    Hospital San Rafael, Barcelona, Spain
    Eur Psychiatry 22:490-8. 2007
    ..We aimed to know the prevalence and clinical features of patients with schizophrenia achieving these outcomes...
  20. ncbi Effect of olanzapine or risperidone treatment on some cognitive functions in a one-year follow-up of schizophrenia outpatients with prominent negative symptoms
    Manuel Gurpegui
    Department of Psychiatry and Institute of Neurosciences, Faculty of Medicine, University of Granada, Av Madrid 11, E 18071 Granada, Spain
    Eur Neuropsychopharmacol 17:725-34. 2007
    ..To compare olanzapine and risperidone outcome on some neurocognitive dimensions in chronic schizophrenia patients with prominent negative symptoms...
  21. ncbi A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia
    Enrique Alvarez
    Department of Psychiatry, Hospital Santa Creu i Sant Pau, Barcelona, Spain
    J Clin Psychopharmacol 26:238-49. 2006
    ..To evaluate the efficacy of olanzapine compared with risperidone in negative symptoms, after 1 year of treatment, in schizophrenic outpatients with prominent negative symptoms...
  22. ncbi Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients
    Julio Bobes
    Facultad de Medicina, Departamento de Psiquiatria, Universidad de Oviedo, Metropolitan Area of Ovieda, Calle Julián Clavería 6, E 33006 Oviedo, Asturias, Spain
    Prog Neuropsychopharmacol Biol Psychiatry 27:473-81. 2003
    ..To assess the safety and effectiveness of olanzapine compared to typical antipsychotics in the treatment of first-episode schizophrenics in acute psychiatric inpatient wards...
  23. ncbi Olanzapine for the treatment of chronic refractory schizophrenia: a 12-month follow-up naturalistic study
    Víctor Rodríguez-Pérez
    Centro Residencial y Rehabilitador San Rafael, C Castro Riberas de Lea, 27260 Lugo, Spain
    Prog Neuropsychopharmacol Biol Psychiatry 26:1055-62. 2002
    ..The aim of this study is to provide long-term data on the effectiveness and safety of olanzapine in a group of patients with severe refractory schizophrenia...